Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
Spotlight survey: flow cytometry in bioanalysis TAKE THE SURVEY

Emerging immuno-oncology therapies

19 Jul 2018
General interest

Current methods for the treatment of cancer include radiation, chemotherapy and surgical intervention, but alternative treatment modalities exist should these traditional methods prove unsuccessful. In this blog post, Dominic Warrino (KCAS; KS, USA), shares his insights into immuno-oncology, and discusses two case studies utilizing antibody drug conjugates and cellular therapies.

Click here to read the full blog post.

LB_Q3-spotlight-view

Top content

  • Chad Briscoe on emerging trends and updates in the biomarker area
  • Blood biomarker panel enhances detection of pancreatic cancer compared to measuring CA19-9 levels alone
  • An automated preanalytical system for oral fluid drug testing

Related tags

cancer immuno-oncology protein
Previous article Next article

Related articles

20 FEB 2015 GENERAL INTEREST
Waters and Ferring collaborate to host Peptide Bioanalysis Forum
14 SEP 2015 CLINICAL
‘Mutation-tracker’ blood test could provide early-warning for cancer relapse
15 MAR 2023 NEWS
Fluorescent biosensor shines light on the activity of the rare-earth metal manganese
14 MAR 2013 GENERAL INTEREST
Detecting oxidized low-density lipoprotein may be the key to identifying and monitoring patients at risk of coronary artery disease
6 FEB 2018 BIOMARKERS
Quantitative immunochromatographic test could aid diagnosis of early heart attack and sepsis
6 MAY 2014 GENERAL INTEREST
Prostate cancer diagnostic offers more specificity than traditional methods
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Bioanalysis Zone